SPECIFIC IN RESPECT TO AMYLOID BETA (A BETA) 1-42 MONOCLONAL ANTIBODIES WITH THERAPEUTIC PROPERTIES

摘要

1. Monoclonal antibody, including any functionally equivalent antibody or its functional fragments, where the antibody is when incubated together with amyloid monomeric peptides, especially β-amyloid monomeric peptides, such as, for example, monomeric Aβ peptides 1-39; 1-40, 1-41, 1-42 or 1-43, but particularly preferably monomeric Aβ1-42 peptides, inhibits the aggregation of Aβ monomers, leading to the formation of high molecular weight polymer fibrils. ! 2. The monoclonal antibody, including any functionally equivalent antibody or its functional fragments according to claim 1, wherein the antibody inhibits the aggregation of Aβ monomers, resulting in the formation of high molecular weight polymer fibrils by at least 50%, especially at least 60%, preferably at least 65%, more preferably at least 75%, even more preferably at least 80%, but most preferably at least 85-90% or more compared to the corresponding monomers of amyloid peptides, torye incubated in buffer (control). ! 3. A monoclonal antibody, including any functionally equivalent antibody or its functional fragments according to claim 1 or 2, where the antibody is co-incubated with amyloid monomeric peptides at a molar concentration ratio of up to 1: 100. ! 4. A monoclonal antibody, including any functionally equivalent antibody or its functional fragments according to claim 3, where the antibody shows the ability to inhibit aggregation when co-incubated with amyloid monomeric peptides at a molar concentration ratio of from 1:30 to 1: 100. ! 5. Monoclonal antibody, including any